Literature DB >> 9120286

Delivery by Trypanosoma cruzi of proteins into the MHC class I antigen processing and presentation pathway.

N Garg1, M P Nunes, R L Tarleton.   

Abstract

Class I MHC-restricted T cell responses have been shown to be critical for the development of immune resistance to Trypanosoma cruzi in mice. However, to date, no antigenic targets of this anti-parasite response have been characterized. We have analyzed the characteristics of potential T. cruzi CTL target molecules by expression of the model CTL target molecule chicken OVA in different cellular compartments of T. cruzi. OVA (amino acids 139-385) was expressed as a secretory, cytoplasmic, transmembrane, or glycosylphosphatidylinositol-anchored protein in T. cruzi transfectants. Host cells infected with T. cruzi transfectants that secreted or released OVA, but not those producing cytoplasmic or transmembrane forms of OVA, could process and present OVA peptide via the class I MHC pathway, as indicated by the stimulation of OVA-specific CD8+ T cell hybridomas and the cytolysis of host cells infected with OVA-secreting parasites by OVA-specific CTLs. In addition, infection of mice with OVA-secreting parasites elicited the production of OVA-specific CTLs. These studies demonstrate the ability to target proteins to specific cellular compartments in T. cruzi using either trypanosomal or mammalian signal sequences. Furthermore, these results suggest that proteins secreted or released by T. cruzi in infected cells are a major source of peptides for MHC class I presentation and for the generation of parasite-specific CTL.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9120286

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

1.  Cutting Edge: Augmenting Muscle MHC Expression Enhances Systemic Pathogen Control at the Expense of T Cell Exhaustion.

Authors:  Angela D Pack; Rick L Tarleton
Journal:  J Immunol       Date:  2020-06-26       Impact factor: 5.422

2.  CD8+ T cells specific for immunodominant trans-sialidase epitopes contribute to control of Trypanosoma cruzi infection but are not required for resistance.

Authors:  Charles S Rosenberg; Dianya L Martin; Rick L Tarleton
Journal:  J Immunol       Date:  2010-06-07       Impact factor: 5.422

3.  Glycosylphosphatidylinositols are required for the development of Trypanosoma cruzi amastigotes.

Authors:  N Garg; M Postan; K Mensa-Wilmot; R L Tarleton
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

4.  Long-Term Immunity to Trypanosoma cruzi in the Absence of Immunodominant trans-Sialidase-Specific CD8+ T Cells.

Authors:  Charles S Rosenberg; Weibo Zhang; Juan M Bustamante; Rick L Tarleton
Journal:  Infect Immun       Date:  2016-08-19       Impact factor: 3.441

5.  Presentation of Toxoplasma gondii antigens via the endogenous major histocompatibility complex class I pathway in nonprofessional and professional antigen-presenting cells.

Authors:  Florence Dzierszinski; Marion Pepper; Jason S Stumhofer; David F LaRosa; Emma H Wilson; Laurence A Turka; Sandra K Halonen; Christopher A Hunter; David S Roos
Journal:  Infect Immun       Date:  2007-09-10       Impact factor: 3.441

6.  Antigen requirements for efficient priming of CD8+ T cells by Leishmania major-infected dendritic cells.

Authors:  Sylvie Bertholet; Alain Debrabant; Farhat Afrin; Elisabeth Caler; Susana Mendez; Khaled S Tabbara; Yasmine Belkaid; David L Sacks
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

Review 7.  CD8+ T cells in Trypanosoma cruzi infection.

Authors:  Rick L Tarleton
Journal:  Semin Immunopathol       Date:  2015-04-29       Impact factor: 9.623

8.  Discriminating Protective from Nonprotective Plasmodium-Specific CD8+ T Cell Responses.

Authors:  Katherine L Doll; Lecia L Pewe; Samarchith P Kurup; John T Harty
Journal:  J Immunol       Date:  2016-04-15       Impact factor: 5.422

9.  Class I major histocompatibility complex presentation of antigens that escape from the parasitophorous vacuole of Toxoplasma gondii.

Authors:  Marc-Jan Gubbels; Boris Striepen; Nilabh Shastri; Mustafa Turkoz; Ellen A Robey
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

10.  Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice.

Authors:  Shivali Gupta; Nisha Jain Garg
Journal:  PLoS Negl Trop Dis       Date:  2010-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.